Compare FRST & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | VNDA |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.1M | 361.4M |
| IPO Year | 2006 | 2005 |
| Metric | FRST | VNDA |
|---|---|---|
| Price | $16.00 | $5.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 259.1K | ★ 858.1K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | $9.63 | $37.40 |
| P/E Ratio | $53.95 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.55 | $4.14 |
| 52 Week High | $16.77 | $9.91 |
| Indicator | FRST | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 31.51 |
| Support Level | $15.21 | $5.11 |
| Resistance Level | $16.77 | $5.58 |
| Average True Range (ATR) | 0.39 | 0.23 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 53.47 | 3.37 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.